Event Details Catalyst Biosciences, Inc. at the World Federation of Hemophilia 2018 Congress May 22, 2018 12:00 PM EDT Supporting Materials Phase 1 Trial of Single and Multiple Dose Subcutaneously Administered Factor IX Variant ISU304/CB 2679d: Pharmacokinetics, Activity and Safety 1.1 MB
Phase 1 Trial of Single and Multiple Dose Subcutaneously Administered Factor IX Variant ISU304/CB 2679d: Pharmacokinetics, Activity and Safety 1.1 MB
Catalyst Biosciences, Inc. at the World Federation of Hemophilia 2018 Congress